Cross Country Healthcare Inc has 10 Schedule 13D or 13G filings on record since 2025-07-16. 3 holders' latest filing reports 5% or more of common stock. Each figure below is the holder's own, as filed, with the filing linked.
Holders
| Holder | Percent | Shares | Latest | Event date |
|---|---|---|---|---|
| Boston Partners | 7.85% | 2,538,481 | SCHEDULE 13G, 2026-05-14 | 2026-03-31 |
| BlackRock, Inc. | 7.5% | 2,468,424 | SCHEDULE 13G/A, 2025-07-16 | 2025-06-30 |
| Dimensional Fund Advisors LP | 5% | 1,609,925 | SCHEDULE 13G/A, 2026-04-09 | 2026-03-31 |
| Magnetar Financial LLC | 4.98% | 1,631,864 | SCHEDULE 13D/A, 2025-12-10 | 2025-12-08 |
| The Goldman Sachs Group, Inc. | 3.9% | 1,271,621 | SCHEDULE 13G/A, 2025-11-12 | 2025-09-30 |
| AllianceBernstein L.P. | 0.1% | 31,215 | SCHEDULE 13G/A, 2026-02-17 | 2025-12-31 |
| The Vanguard Group | 0% | 0 | SCHEDULE 13G/A, 2026-03-26 | 2026-03-13 |
Purpose of Transaction (Item 4)
Magnetar Financial LLC
Since the filing of the Schedule 13D Amendment 2 on December 8, 2025, the Reporting Persons sold 183,678 Shares on December 8, 2025 reported herein, which consists of 113,242 Shares sold for the benefit of PRA Master Fund, 48,351 Shares sold for the benefit of Systematic Master Fund, 10,777 Shares sold for the benefit of Relative Value Master Fund and 11,308 Shares sold for the benefit of two Managed Accounts. Each of the Reporting Persons reserves the right to acquire or dispose additional securities of the Company in the open market, in privately negotiated transactions, or otherwise, to dispose of all or a portion of the Shares and/or other securities reported in this Statement, or to change their intention with respect to any or all of the matters referred to in this Item 4. Other than as described above in this Item 4, the Reporting Persons do not have any plans or proposals that relate to, or would result in, any actions or events specified in clauses (a) through (j) of Item 4 to Schedule 13D.Item 4 of the SCHEDULE 13D/A filed 2025-12-10
Timeline
| Filed | Holder | Percent | Filing |
|---|---|---|---|
| 2025-07-16 | BlackRock, Inc. | 7.5% | SCHEDULE 13G/A |
| 2025-08-13 | The Goldman Sachs Group, Inc. | 5.8% | SCHEDULE 13G/A |
| 2025-11-12 | The Goldman Sachs Group, Inc. | 3.9% | SCHEDULE 13G/A |
| 2025-11-14 | AllianceBernstein L.P. | 5.9% | SCHEDULE 13G/A |
| 2025-12-08 | Magnetar Financial LLC | 5.54% | SCHEDULE 13D/A |
| 2025-12-10 | Magnetar Financial LLC | 4.98% | SCHEDULE 13D/A |
| 2026-02-17 | AllianceBernstein L.P. | 0.1% | SCHEDULE 13G/A |
| 2026-03-26 | The Vanguard Group | 0% | SCHEDULE 13G/A |
| 2026-04-09 | Dimensional Fund Advisors LP | 5% | SCHEDULE 13G/A |
| 2026-05-14 | Boston Partners | 7.85% | SCHEDULE 13G |
Tools for this story
Each opens in a new tab, filled in for Cross Country Healthcare Inc. With no account yet, you sign up free and land on the result.
Where this comes from
Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.
Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.